Article
Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.
Clinical and vaccine immunology : CVI - 1 Feb 2015
Struyf Frank, Colau Brigitte, Wheeler Cosette M, Naud Paulo, Garland Suzanne, Quint Wim, Chow Song-Nan, Salmerón Jorge, Lehtinen Matti, Del Rosario-Raymundo M Rowena, Paavonen Jorma, Teixeira Júlio C, Germar Maria Julieta, Peters Klaus, Skinner S Rachel, Limson Genara, Castellsagué Xavier, Poppe Willy A J, Ramjattan Brian, Klein Terry D, Schwarz Tino F, Chatterjee Archana, Tjalma Wiebren A A, Diaz-Mitoma Francisco, Lewis David J M, Harper Diane M, Molijn Anco, van Doorn Leen-Jan, David Marie-Pierre, Dubin Gary
Abstract excerpt
The efficacy of the human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against cervical infections with HPV in the Papilloma Trial against Cancer in Young Adults (PATRICIA) was evaluated using a combination of the broad-spectrum L1-based SPF10 PCR-DNA enzyme immunoassay (DEIA)/line probe assay (LiPA25) system with type-specific PCRs for HPV-16 and -18. Broad-spectrum PCR assays may underestimate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.